by Stacey Hawkins | Apr 9, 2015 | Groundbreaking New Therapies in Development
Billion Dollar Mechanisms Of Action The Most Promising Drugs of 2015—a Thomson Reuters Cortellis Competitive Intelligence report—includes several new drugs with predicted sales of $1 billion plus by 2019. Those on the list are well on their way to winning or have... by Stacey Hawkins | Jan 8, 2015 | Regulation
The FDA ushered in six new drugs just before the close of 2014, bringing the final tally to 41– the highest rate since 1996, when the agency approved 53 drugs. 2014 drug approvals were notable not only for their quantity, but also their quality. A number of new drugs... by Stacey Hawkins | Oct 30, 2014 | Immunotherapies
Since their premier on the scene, monoclonal antibodies (mAb) have demanded top billing on the biotech marquee, creating a cast of therapeutics used to treat diseases like autoimmune disorders and cancer. The first player debuted in 1986 when Janssen-Cilag’s... by Stacey Hawkins | Jul 31, 2014 | Uncategorized
PLAYING DETECTIVE WITH CHECKPOINT THERAPIES Over the past two weeks, we have discussed cancer immunotherapies that involve training T-cells (the detective warriors of our immune system) into seeking and destroying cancer cells. This week, we will take a look into... by Stacey Hawkins | Jul 24, 2014 | Uncategorized
PRIMED TO BEAT PROSTATE CANCER We usually associate vaccines with infectious disease—measles, mumps, and polio. This 20th century miracle of medicine is being rolled out again, but this time with a 21st century mission: target cancer. In this week’s issue, we will...
